Development Level

Tbio 102 | 10,625
Tchem 23 | 1,890
Tdark 4 | 7,003
Tclin 3 | 602

Collection

Kinase: IDG Consortium (Targets) 1 | 125

IMPC Phenotype

preweaning lethality, complete... 7 | 633
abnormal behavior 4 | 226
decreased body weight 3 | 174
decreased lean body mass 3 | 195
increased bone mineral density 3 | 52
abnormal bone mineralization 2 | 55
abnormal bone structure 2 | 131
abnormal embryo size 2 | 112
abnormal retina morphology 2 | 100
decreased bone mineral content 2 | 157
decreased circulating choleste... 2 | 85
decreased circulating creatini... 2 | 31
decreased circulating total pr... 2 | 41
decreased grip strength 2 | 123
decreased total body fat amoun... 2 | 186
embryonic lethality prior to o... 2 | 148
increased exploration in new e... 2 | 56
increased hemoglobin content 2 | 45
increased lean body mass 2 | 107
abnormal QRS complex 1 | 25
abnormal behavioral response t... 1 | 52
abnormal femur morphology 1 | 14
abnormal head morphology 1 | 10
abnormal optic disc morphology 1 | 10
abnormal retinal pigmentation 1 | 61
abnormal skin morphology 1 | 23
abnormal sleep behavior 1 | 63
abnormal startle reflex 1 | 14
abnormal tail movements 1 | 12
abnormal tooth morphology 1 | 24
decreased NK cell number 1 | 16
decreased T cell number 1 | 31
decreased blood urea nitrogen ... 1 | 31
decreased bone mineral density 1 | 126
decreased circulating HDL chol... 1 | 77
decreased circulating LDL chol... 1 | 37
decreased circulating alanine ... 1 | 53
decreased circulating free fat... 1 | 39
decreased circulating glucose ... 1 | 121
decreased circulating insulin ... 1 | 75
decreased circulating iron lev... 1 | 25
decreased circulating serum al... 1 | 79
decreased circulating triglyce... 1 | 83
decreased coping response 1 | 5
decreased effector memory CD8-... 1 | 24
decreased eosinophil cell numb... 1 | 41
decreased fasted circulating g... 1 | 49
decreased lactate dehydrogenas... 1 | 14
decreased leukocyte cell numbe... 1 | 54
decreased lumbar vertebrae num... 1 | 62
decreased mature B cell number 1 | 25
decreased spleen weight 1 | 13
decreased threshold for audito... 1 | 32
decreased vertical activity 1 | 22
edema 1 | 11
embryonic lethality prior to t... 1 | 187
enlarged lymph nodes 1 | 27
enlarged pancreas 1 | 1
enlarged spleen 1 | 26
hyperactivity 1 | 108
impaired glucose tolerance 1 | 52
increased CD8-positive, naive ... 1 | 3
increased blood urea nitrogen ... 1 | 44
increased body weight 1 | 42
increased bone mineral content 1 | 92
increased fasted circulating g... 1 | 68
increased mean corpuscular hem... 1 | 93
increased respiratory quotient 1 | 12
increased total body fat amoun... 1 | 57
increased vertical activity 1 | 18
prenatal lethality 1 | 16
prenatal lethality prior to he... 1 | 64
preweaning lethality, incomple... 1 | 260
short tibia 1 | 82
shortened PQ interval 1 | 6
shortened PR interval 1 | 5
shortened RR interval 1 | 19
thrombocytopenia 1 | 46

Disease

ovarian cancer 75 | 8,491
osteosarcoma 69 | 7,933
psoriasis 64 | 6,685
glioblastoma 61 | 5,572
medulloblastoma, large-cell 61 | 6,234
atypical teratoid / rhabdoid tumor 56 | 4,369
Cancer 48 | 2,346
lung cancer 46 | 4,473
Carcinoma 45 | 2,147
pancreatic cancer 43 | 2,300
pilocytic astrocytoma 43 | 3,086
intraductal papillary-mucinous neoplasm (IPMN) 41 | 3,289
lung adenocarcinoma 39 | 2,714
non-small cell lung cancer 39 | 2,798
intraductal papillary-mucinous carcinoma (IPMC) 38 | 2,988
pediatric high grade glioma 37 | 2,712
invasive ductal carcinoma 36 | 2,950
Breast cancer 34 | 3,098
interstitial cystitis 34 | 2,299
lung carcinoma 31 | 2,844
malignant mesothelioma 31 | 3,163
primitive neuroectodermal tumor 31 | 3,031
oligodendroglioma 30 | 2,849
subependymal giant cell astrocytoma 29 | 2,287
intraductal papillary-mucinous adenoma (IPMA) 28 | 2,956
primary pancreatic ductal adenocarcinoma 28 | 1,271
ependymoma 25 | 2,514
group 4 medulloblastoma 25 | 1,875
ductal carcinoma in situ 24 | 1,745
breast carcinoma 23 | 1,614
pituitary cancer 23 | 1,972
adult high grade glioma 22 | 2,148
astrocytic glioma 21 | 2,241
cystic fibrosis 19 | 1,670
medulloblastoma 19 | 1,524
posterior fossa group A ependymoma 19 | 1,511
tuberculosis 19 | 1,563
ulcerative colitis 19 | 2,087
sonic hedgehog group medulloblastoma 17 | 1,482
astrocytoma 16 | 1,493
colon cancer 16 | 1,475
Rheumatoid Arthritis 15 | 1,170
juvenile dermatomyositis 14 | 1,189
cutaneous lupus erythematosus 13 | 1,056
diabetes mellitus 13 | 1,663
esophageal adenocarcinoma 13 | 737
gastric carcinoma 13 | 832
posterior fossa group B ependymoma 13 | 1,530
spina bifida 13 | 1,064
Alzheimer's disease 12 | 644
Down syndrome 12 | 548
dermatomyositis 12 | 966
active Crohn's disease 11 | 918
adrenocortical carcinoma 11 | 1,427
atypical teratoid/rhabdoid tumor 11 | 1,095
pancreatic ductal adenocarcinoma liver metastasis 11 | 1,795
Mammary Neoplasms 10 | 410
Obesity 10 | 616
Pick disease 10 | 1,893
acute myeloid leukemia 10 | 785
Duchenne muscular dystrophy 9 | 602
Epidermolysis bullosa 9 | 21
Prostatic Neoplasms 9 | 471
Vascular disease 9 | 281
Waldenstrons macroglobulinemia 9 | 764
nasopharyngeal carcinoma 9 | 1,056
Intellectual disability 8 | 573
Kidney disease 8 | 397
active ulcerative colitis 8 | 477
group 3 medulloblastoma 8 | 2,254
Atopic dermatitis 7 | 944
Colorectal Neoplasms 7 | 217
Multiple Sclerosis 7 | 498
Multiple myeloma 7 | 1,327
Osteoporosis 7 | 259
acute quadriplegic myopathy 7 | 1,157
interstitial lung disease 7 | 292
non-small cell lung carcinoma 7 | 413
primary Sjogren syndrome 7 | 788
Barrett's esophagus 6 | 185
Liver carcinoma 6 | 217
Polycystic Ovary Syndrome 6 | 334
Stomach Neoplasms 6 | 282
autosomal dominant Emery-Dreifuss muscular dystrophy 6 | 499
fibroadenoma 6 | 557
mucosa-associated lymphoid tissue lymphoma 6 | 480
tuberculosis and treatment for 6 months 6 | 686
Adult junctional epidermolysis bullosa (disorder) 5 | 5
Autistic Disorder 5 | 320
Bullous pemphigoid 5 | 17
Inflammatory bowel disease 5 | 142
Junctional epidermolysis bullosa 5 | 9
Myopia 5 | 99
Neoplasm Invasiveness 5 | 127
Neoplasm Metastasis 5 | 138
Proteinuria 5 | 63
non primary Sjogren syndrome sicca 5 | 840
pancreatic carcinoma 5 | 567
tuberculosis and treatment for 3 months 5 | 327
Schizophrenia 4 | 503

Tissue

Digestive Tract 131 | 18,472
Endocrine System 131 | 18,511
Female tissues 131 | 18,646
Nervous System 131 | 18,560
Urinary Tract 131 | 18,443
Blood and immune system 130 | 17,994
Cardiovascular System 130 | 17,957
Liver and Pancreas 130 | 18,135
Male tissues 130 | 17,968
Skin and soft tissues 130 | 18,114
Respiratory system 129 | 17,483

Target Family

Non-IDG 105 | 11,969
Kinase 17 | 634
Enzyme 10 | 4,146

Reactome Pathway

Cell-Cell communication 132 | 132
Signal Transduction 2,515 | 2,515
Immune System 2,183 | 2,183
Metabolism 2,131 | 2,131
Gene Expression 1,754 | 1,754
Metabolism of proteins 1,544 | 1,544
Innate Immune System 1,375 | 1,375
Signaling by GPCR 1,329 | 1,329
Developmental Biology 1,028 | 1,028
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,004 | 1,004
Adaptive Immune System 938 | 938
Disease 855 | 855
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 803 | 803
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 668 | 668
Membrane Trafficking 608 | 608
Cell Cycle 572 | 572
Neutrophil degranulation 542 | 542
Axon guidance 541 | 541
Signaling by Interleukins 500 | 500
Cell Cycle, Mitotic 470 | 470
Signalling by NGF 467 | 467
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 435 | 435
Class I MHC mediated antigen p... 430 | 430
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 423 | 423
Cellular responses to stress 415 | 415
DAP12 interactions 409 | 409
Infectious disease 391 | 391
NGF signalling via TRKA from t... 378 | 378
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 367 | 367
Diseases of signal transductio... 359 | 359
Transcriptional Regulation by ... 356 | 356
Signaling by EGFR 355 | 355
Metabolism of amino acids and ... 353 | 353
DAP12 signaling 346 | 346
Downstream signal transduction 343 | 343
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 329 | 329
Signaling by SCF-KIT 327 | 327
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 321 | 321
FCERI mediated MAPK activation 316 | 316
Signaling by Insulin receptor 312 | 312
Antigen processing: Ubiquitina... 301 | 301
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 290 | 290
Signaling by Wnt 290 | 290
IGF1R signaling cascade 289 | 289
IRS-related events triggered b... 289 | 289
Insulin receptor signalling ca... 288 | 288
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 285 | 285
MAPK family signaling cascades 283 | 283
Asparagine N-linked glycosylat... 282 | 282
Signaling by the B Cell Recept... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 277 | 277
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 268 | 268
M Phase 266 | 266
Interleukin-3, 5 and GM-CSF si... 262 | 262
RET signaling 261 | 261
Signalling to ERKs 254 | 254
Interleukin-2 signaling 253 | 253
Immunoregulatory interactions ... 252 | 252
RHO GTPase Effectors 249 | 249
VEGFR2 mediated cell prolifera... 249 | 249
Signalling to RAS 247 | 247
Interleukin receptor SHC signa... 246 | 246
G alpha (i) signalling events 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Signaling by Leptin 244 | 244
Prolonged ERK activation event... 243 | 243
MAPK1/MAPK3 signaling 242 | 242
Frs2-mediated activation 241 | 241
HIV Infection 241 | 241
ARMS-mediated activation 240 | 240
Signalling to p38 via RIT and ... 240 | 240
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 236 | 236
RAF/MAP kinase cascade 236 | 236
SHC1 events in EGFR signaling 236 | 236
SOS-mediated signalling 236 | 236
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Phospholipid metabolism 202 | 202

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Mitogen-activated protein kinase 12 MAPK12 Tchem Kinase -1.91165 83.2 324
Protein kinase C iota type PRKCI Tchem Kinase -1.69816 51.8 122
Cell adhesion molecule 1 CADM1 Tbio Non-IDG -2.73938 508.3 380
Cytoplasmic protein NCK2 NCK2 Tbio Non-IDG -1.56739 34.8 215
Spectrin alpha chain, non-erythrocytic 1 SPTAN1 Tbio Non-IDG -2.41058 258.0 266
Ras-related C3 botulinum toxin substrate 1 RAC1 Tbio Enzyme -1.87449 73.5 395
Collagen alpha-1(XVII) chain COL17A1 Tbio Non-IDG -2.72832 547.0 90
Filamin-C FLNC Tbio Non-IDG -2.88672 775.5 91
Claudin-18 CLDN18 Tchem Non-IDG -1.57275 38.7 120
Claudin-9 CLDN9 Tbio Non-IDG -0.87632 6.84 58